Unicycive
  • Company
  • Therapeutic Focus
  • Pipeline
    • UNI-494
    • Renazorb
  • Investors
  • Contact

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Jul 13, 2021 8:30am EDT

Unicycive Therapeutics Announces Pricing of Initial Public Offering

Dec 14, 2020 9:30am EST

Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease

Jun 16, 2020 9:38am EDT

Keith Ward, Ph.D. Joins as the Chief Development Officer of Unicycive

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Legal Notices and Terms of Use
Privacy Policy
Ad and Cookie Policy
Contact Us >

Copyright © 2023 Unicycive

  • Twitter
  • LinkedIn